Park DW, Kwon O, Jang JS, et al. - In order to determine the safety as well as the efficacy of potent P2Y12 inhibitor ticagrelor in East Asian populations, researchers undertook this multicenter trial, wherein, they assessed clinically significant bleeding (a composite of major bleeding or minor bleeding according to Platelet Inhibition and Patient Outcomes criteria (at 12 months) in participants—Korean patients (n = 800) hospitalized for acute coronary syndromes with or without ST elevation and intended for invasive management— who were randomized 1:1 to ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (600 mg loading dose, 75 mg daily thereafter). Among participants, a higher incidence of clinically significant bleeding was reported in relation to treatment with standard-dose ticagrelor vs clopidogrel. Exercising caution is recommended while interpreting the numerically higher incidence of ischemic events, given this study was underpowered to reach any conclusion about efficacy.